X4 Pharmaceuticals, Inc. (XFOR) intrinsic value & 10-year financials
X4 Pharmaceuticals, Inc. (XFOR) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 39.0% a year to $35.1M, with an average return on invested capital of 416.1%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $2.59
- Market cap
- $109.5M
- Revenue (FY2025)
- $35.1M
- Revenue growth (10-yr CAGR)
- 39.0%
- ROIC (10-yr avg)
- 416.1%
- Free cash flow (FY2025)
- -$85.6M
XFOR 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $35.1M | -$79.2M | -$1.87 | -$85.6M | -247.4% | -199.5% |
| FY2024 | $2.6M | -$37.5M | -$0.19 | -$131.2M | -1423.6% | -140.2% |
| FY2023 | $0 | -$101.2M | -$0.57 | -$96.6M | — | 15582.9% |
| FY2022 | $0 | -$93.9M | -$1.52 | -$77.2M | — | -1608.2% |
| FY2021 | $0 | -$88.7M | -$3.99 | -$71.5M | — | -320.6% |
| FY2020 | $3.0M | -$62.1M | -$3.09 | -$60.2M | -1995.8% | -211.2% |
| FY2019 | $0 | -$52.8M | — | -$48.2M | — | -400.8% |
| FY2018 | $3.5M | -$43.0M | — | -$40.9M | -1311.0% | -5423.8% |
| FY2017 | — | -$33.9M | — | -$27.9M | — | -3158.7% |
| FY2016 | — | -$23.0M | — | -$21.7M | — | 40.6% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
X4 Pharmaceuticals, Inc revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
X4 Pharmaceuticals, Inc has historically struggled to out-earn its cost of capital, averaging just -5.7% ROIC.
X4 Pharmaceuticals, Inc capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, X4 Pharmaceuticals, Inc is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-62.11 per share.